When reactive oxygen species (ROS) accumulate in the
body, they
can lead to inflammatory bowel disease (IBD) through their oxidative
damages to DNA, proteins, and lipids. In this study, a thermosensitive
hydrogel-based nanozyme was developed to treat IBD. We first synthesized
a manganese oxide (Mn3O4) nanozyme with multienzyme
activity followed by physically loading with a thermosensitive hydrogel
poly(d,l-lactide)-poly(ethylene glycol)-poly(d,l-lactide)-based triblock copolymer (PDLLA-PEG-PDLLA).
Then, a mouse model based on the inducement of dextran sulfate sodium
(DSS) was built to assess the ROS targeting, scavenging, as well as
anti-inflammatory ability of Mn3O4 nanozymes-loaded
PDLLA-PEG-PDLLA (MLPPP). Because of the sharp gelation behavior of
PDLLA-PEG-PDLLA in body temperature, the MLPPP nanozyme can easily
target the inflamed colon after colorectal administration. Following
the formation of a physical protection barrier and sustained release
of manganese oxide nanozymes that had diverse enzymatic activities
and can effectively scavenge ROS, the administration of the MLPPP
nanozyme had a high efficacy for treating colitis mice; importantly,
after the treatment with this novel nanoformulation, the levels of
the pathological indicators in colons as well as in sera of colitis
mice were even comparable to healthy mice. Therefore, the MLPPP nanozyme
has a potential application for nanotherapy of IBD and would have
great clinical translation prospects.